These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18329876)

  • 1. Sulfonamidolactam inhibitors of coagulation factor Xa.
    Smallheer JM; Wang S; Laws ML; Nakajima S; Hu Z; Han W; Jacobson I; Luettgen JM; Rossi KA; Rendina AR; Knabb RM; Wexler RR; Lam PY; Quan ML
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2428-33. PubMed ID: 18329876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
    Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand.
    Nazaré M; Matter H; Klingler O; Al-Obeidi F; Schreuder H; Zoller G; Czech J; Lorenz M; Dudda A; Peyman A; Nestler HP; Urmann M; Bauer A; Laux V; Wehner V; Will DW
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2801-5. PubMed ID: 15125936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
    Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
    J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
    J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
    Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
    Franciskovich JB; Masters JJ; Tinsley JM; Craft TJ; Froelich LL; Gifford-Moore DS; Klimkowski VJ; Smallwood JK; Smith GF; Smith T; Towner RR; Weir LC; Wiley MR
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4838-41. PubMed ID: 16140530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
    Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
    Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
    Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
    Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
    Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.